Astellas' Prosidion Ltd. subsidiary granted AstraZeneca an exclusive option to acquire Type II diabetes compounds PSN821 and PSN842

Astellas Pharma Inc.

Japan / Mid-Cap Biopharma ($1-$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

AstraZeneca plc

U.K. / Large-Cap Biopharma (>=$50 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Terminated

Sample

01/01/2009

announced

01/01/2009

Terminated